Views & Analysis | Perspectives on pharma industry issues

Digital

Healthcare AI’s off switch needs a budget

An AI system can be cheap to buy and expensive to stop.

Patients

Union Jack on pill, one of many scattered on aqua surface

Rare diseases, real opportunity: Why the UK’s next challenge...

The UK has the science, the talent, and the investment. The next step is ensuring that innovation translates into timely patient impact.

Market Access

Chinese flag atop pills on black background

Is the next generation of Chinese biotech ready to go global...

Will Chinese biotechs continue to transfer most ex-China rights, or retain their strongest assets and compete internationally themselves?

Sales & Marketing

The independent pharmacy opportunity pharma marketers are ov...

Pharma marketers often underestimate the value of independent pharmacies.

R&D

Sponsored

Turning recruitment potential into enrolment reality

In the fourth episode of the IQVIA-sponsored PSCS leadership video series, Karen Townsend, senior director of medical affairs discusses SEELs

Articles

A beginner’s guide to digital pharma: part 2 – start with a ...

If you’re not sure where to start with a digital strategy, remember to keep it simple and remember it’s all about the customer. Here are our thoughts on planning ahead. It's always hard to outline a digital strategy, when the rules are so ambiguous. However, it’s really quite...

Articles

A beginner’s guide to digital pharma: part 3 – websites

Continuing our beginner’s guide to digital strategy, this week we look at that most mature of online engagement tools. Read on for our top tips on making great websites. So you’ve finally convinced your boss to give you a budget for your fancy disease area website (or even brand website if you’re sat in the US!)…

Articles

A beginner’s guide to digital pharma: part 4 – Twitter

Next up in our beginner’s guide to digital pharma we take a look at the phenomenon that is Twitter. Has the little blue bird entered your life yet? Read on to get started! With over 140 million “Tweets” sent every day and over 400,000 people joining on a daily basis, is this something worth ignoring as part of …

Sales & Marketing

The independent pharmacy opportunity pharma marketers are ov...

Pharma marketers often underestimate the value of independent pharmacies.

Sales & Marketing

Sponsored

Accelerating growth through strategic investment in healthca...

CEVA FORPATIENTS at Rockingham, UK will offer the healthcare supply chain a new, sustainably designed multi-user site.

Digital

Healthcare AI’s off switch needs a budget

An AI system can be cheap to buy and expensive to stop.

Digital

Sponsored

AI-enabled pharmacovigilance, with Updesh Dosanjh

Updesh Dosanjh, IQVIA commercialisation lead for safety technology, discusses how and why the role of AI in pharmacovigilance is changing.

Market Access

Is the next generation of Chinese biotech ready to go global...

Will Chinese biotechs continue to transfer most ex-China rights, or retain their strongest assets and compete internationally themselves?

Market Access

Two business hands outstretched, one weighing cash, the other drugs, for balance

What the revised 340B rebate pilot programme means for pharm...

While the scope of the revised pilot is limited, it may be a harbinger for a broader policy shift.

Oncology

Australia, CAR-T therapy, and solid tumours

Bev Menner, chief executive officer at Cell Therapies Pty Ltd, discusses CAR-T therapies for solid tumours and Australian and APAC R&D more generally.

Oncology